CUHK study reveals "CD8⁺ regulatory T cells" as a novel therapeutic target for atherosclerosis

The Faculty of Medicine at The Chinese University of Hong Kong has revealed that "CD8⁺ regulatory T cells" can serve as a novel therapeutic target against atherosclerosis. The team found that "effector CD8⁺ T cells" affect the normal functioning of vascular cells, accelerating the progression of atherosclerosis. The study further confirmed that inducing protective CD8⁺ Tregs with a non-cytolytic anti-CD8α antibody can restore Notch signalling in vascular cells, inhibit abnormal proliferation and slow the progression of the disease.